The ocular microenvironment has adapted several negative regulators of inflammation to maintain immune privilege and health of the visual axis. Several constitutively produced negative regulators within the eye TGF-2, -melanocyte stimulating hormone ( -MSH), Fas ligand (FasL), and PD-L1 standout because of their capacity to influence multiple pathways of inflammation, and that they are part of promoting immune tolerance. These regulators demonstrate the capacity of immune privilege to prevent the activation of inflammation, and to suppress activation of effector immune cells even under conditions of ocular inflammation induced by endotoxin and autoimmune disease. In addition, these negative regulators promote and expand immune cells that mediate regulatory and tolerogenic immunity. This in turn makes the immune cells themselves negative regulators of inflammation. This provides for a greater understanding of immune privilege in that it includes both molecular and cellular negative regulators of inflammation. This would mean that potentially new approaches to the treatment of autoimmune disease can be developed through the use of molecules and cells as negative regulators of inflammation.
INTRODUCTION
The eye is an immune privileged tissue that has adapted several negative regulators to prevent the activation of inflammation within its tissue microenvironment. Ocular immune privilege was originally described by the indefinite survival of histoincompatible grafts placed within the anterior chamber. 1, 2 Today, immune privilege is described also by soluble and cell membrane bound molecules constitutively produced by cells of the ocular microenvironment. These molecules suppress inflammation, and trigger checkpoints in immunity. [3] [4] [5] [6] Moreover, these molecules do not just suppress inflammation, but program monocytes, and T cells to mediate tolerance.
The mechanisms of ocular immune privilege can be separated into physical, molecular, and cellular barriers to the induction of inflammation. The physical barriers are the tight junctions of endothelial cells, and the retinal pigment epithelial (RPE) cell monolayer that form the blood-ocular barrier. 7, 8 This barrier is sufficient to inhibit the migration of immune cells from the circulation into the eye. 9 Also, it allows Abbreviations: -MSH, -melanocyte stimulating hormone; ACAID, anterior chamber-associated immune deviation; FasL, Fas ligand; iTreg, inducible Treg; RPE, retinal pigment epithelial; Tregs, regulatory T cells; TSP-1, thrombospondin-1; WT, wild-type the eye to bathe its own cells with molecules needed for metabolism, neuroretinal function, regulation of intraocular pressure, and the accumulation of anti-inflammatory factors. In addition, there are no known direct lymphatic drainage of the ocular microenvironment further isolating the ocular microenvironment from conventional pathways to induce inflammation and immunity. 10 These were once considered the sole reason for survival of the incompatible grafts placed into the anterior chamber of the eye because of an exclusion of peripheral immune cell migration, and sequestration of Ags in the ocular microenvironment. However, it is clear that the immune system is very much aware of Ags placed in the ocular microenvironment. [11] [12] [13] [14] Inoculation of Ags into the eye does not induce inflammatory immune responses, but instead induce tolerance that is specific to the Ag. 11 This is exemplified by treating APC with aqueous humor (the fluid filling the ocular anterior chamber), or with conditioned media of primary RPE cell cultures. [15] [16] [17] [18] [19] [20] [21] [22] [23] These ocular influenced APC process and present Ag in a manner that induce Ag-specific regulatory CD4 and CD8 T cells. [24] [25] [26] In addition, contact with RPE cell causes naive negative regulators of inflammation that make the immune system regulate itself.
These mechanisms allow for medical interventions that are not possible in other tissues. The most noted is that blood typing is not needed for a successful corneal transplant in low risk patients. [30] [31] [32] This has been linked to the ocular microenvironment to generate specific tolerance to alloantigen expressed in the transplanted cornea. 30, 33, 34 Clinical trials of AAV2 delivery of hRPE65 genes show little to no immune response against the virus even with multiple applications of the virus into the eye. [35] [36] [37] Direct evidence as to why has not been reported, but the injection of viral proteins into the ocular microenvironment may be inducing systemic tolerance to viral Ags. This is a phenomenon called immune deviation, and would permitting multiple injections of AAV without immune response. 11, 38, 39 In addition, long-term survival of embryonic stem cells has been seen in clinical studies with the cells injected into the subretinal space. 37, 40, 41 It has been found that transplanted RPE cells can create immune privileged microenvironments; therefore, transplanting retinal cells may themselves produce factors that prevent rejection. [42] [43] [44] In contrast, ocular immune privilege may cause complications in patients infected with Ebola virus.
Even during recovery there is a persistence of virus in the eye taking advantage of the ocular microenvironment to hide from the substantial immune response raging against it. [45] [46] [47] Understanding the mechanisms of ocular immune privilege will provide the knowledge into what is necessary to maintain, and in disease to restore a healthy ocular microenvironment.
ESSENTIAL NEGATIVE REGULATORS OF IMMUNITY IN IMMUNE PRIVILEGE
The uniqueness of the ocular microenvironment is that negative regulators of inflammation are constitutively expressed under healthy conditions. The source of the soluble regulators are the iris and ciliary body cells that generated aqueous humor, and recently it has become clear that RPE cells are another source of the regulators. [19] [20] [21] [22] 27 ,48-52 These regulators are growth factors, neuropeptides, cytokines, and complement inhibitors. Collectively, these regulators suppress the activation of inflammatory activity, induce production of anti-inflammatory cytokines, and promote immune tolerance activity in monocytes and T cells. 17, 19, 20, 23 Individually these regulators affect different cells of inflammation (Table 1A) . Also, they mediate the activation of tolerogenic APC, and regulatory T cells (Tregs), which in turn act as cellular negative regulators of inflammation (Table 1B) . The most noted regulators are the immunosuppressive cytokine TGF-2, the immunomodulating neuropeptide alpha-melanocyte stimulating hormone ( -MSH), and the check point membrane expressed molecules PD-L1 and Fas ligand (FasL). 16, [53] [54] [55] [56] [57] [58] 
Transforming growth factor-2
The initial work done to understand the molecular negative regulators of immune privilege was done studying the effects of aqueous humor on APCs. 23 When the activity of TGF-2 is neutralized or left latent, aqueous humor is still able to suppress effector T cell activation. 
Neuropeptide -MSH
Several immunomodulating neuropeptides are found in aqueous humor, and are produced by RPE. 16 [80] [81] [82] [83] There is constitutive expression of -MSH in healthy aqueous humor and in the conditioned media of cultured RPE cells at concentrations that are highly anti-inflammatory. 16, 21 Tissue or systemic injections of -MSH suppress inflammation mediated by endotoxin, and proinflammatory cytokines IL-1 and TNF-. [84] [85] [86] [87] [88] [89] [90] At the cellular level -MSH suppresses macrophage, dendritic cell, and neutrophil generation of reactive oxygen intermediates, nitric oxide, proinflammatory cytokines, and migration. [91] [92] [93] [94] [95] [96] Also, there is induction of an anti-inflammatory autocrine loop where -MSH enhances its own receptor expression and production in macrophages. 96 Macrophages treated with -MSH and stimulated through TLR4 with endotoxin are suppressed in NFkB activation. [97] [98] [99] [100] [101] [102] Suppression of inflammatory activity stimulated through other TLRs may also be suppressed by -MSH. 103, 104 The -MSH-treated macrophages have enhanced expression of IL-1R-associated kinase (IRAK)-M that blocks MyD88 intracellular pathways of inflammation. 105 Recently reported is that -MSH suppress phagocytic uptake of bioparticles through scavenger-receptor meditated pathways, but not through FcR-mediated pathways. 106 Although uptake of opsonized-Ag is not suppressed by -MSH, the activation of the phagolysosome is suppressed. 106 In addition, this is further enhanced by the cotreatment of macrophages with -MSH and Neuropeptide Y (NPY), another neuropeptide found constitutively present in the eye and produced by RPe cells. 21, 106 This has suggested that within the immune privileged ocular microenvironment there is a mechanism to allow phagocytes to remove harmful materials without induction of inflammation. Also, this is done without conventional processing and presentation of Ag that could be recognized by autoreactive effector T cells expanded in the periphery. The effects of -MSH are not just suppression of inflammatory activity, -MSH programs anti-inflammatory activity in stimulated macrophages. 20, 107, 108 Similar effects have been seen in activated macrophages treated with aqueous humor or conditioned media of cultured RPE cell mediated by -MSH. 20, 23 Aqueous humor suppresses CD4 + T cells production of IFN-, and this is mediated by -MSH. 109 The suppression of the proinflamma- 
Membrane bound negative regulators
T cells express regulatory activity when they come in contact with cultured RPE. 42, 52, 57, 116 
Cellular negative regulators of inflammation
The negative regulators of inflammation expressed within the eye, not only suppress production of proinflammatory cytokines, but also program immune cells to suppress inflammation and promote tolerance.
This makes immune privilege more than the constitutive presence of molecular regulators of inflammation, but also immune cells that act as cellular negative regulators of inflammation. 73, 79, 115 When the MC5r knockout mice are reimmunized to the retinal autoantigen after recovery from EAU they display a recall response with rapid development and severe uveitis. 122 This is in contrast to reimmunized WT mice recovered from EAU that show a naive immune response with delayed and mild uveitis. As the eyes recover from uveitis, they appear to be using the mechanisms of immune privilege and tolerance to restore an anti-inflammatory microenvironment.
It is not clear if this is possible in every human with uveitis, but the negative regulators of immunity within the eye are evolutionarily conserved in expression and function. It is possible that species variance in the strengths of these regulatory pathways are associated with susceptibility and recovery to autoimmune disease.
Microglial cells of the retina are potential cellular regulators of inflammation. 21, [123] [124] [125] Microglial cells are resident immune cells of the brain and retina that are derived from yolk sac blood islands. [126] [127] [128] Although they have the potential to express MHC class II, they do so at a very low level. 124, 129 Microglial cells perform immune surveillance, and activate upon pathologic changes. [130] [131] [132] Even the slightest changes like bright light injury, microglial cells adopted an amoeboid shape and moved to the site of retinal injury. 133 In the inflamed retina macrophages and microglial cells up-regulate their expression of iNOS and produce of proinflammatory cytokines including TNF-, IL-1, CCL22. 21, 134, 135 However, microglial cells in the healthy retina may have a more anti-inflammatory function mediated by the negative regulators of -MSH and NPY produced by RPE, and by CD200 expressed on neural and epithelial cells of the retina. 21, 136 When microglial cells in healthy retinas were stained for the proinflammatory enzyme iNOS and for the anti-inflammatory marker enzyme Arginase-1 they costained for both. 21 The coexpression of iNOS with Arginase-1 is a characteristic of myeloid suppressor cells. 137, 138 When the retina is injured this coexpression is lost, and corresponds with diminished production of -MSH by RPE. 21 This makes the microglial cells sentinels of immune privilege. Their expression of myeloid suppressor cell activity means that they prevent T cell activation and suppressive activity that would induce inflammation. Changes in their activity would have a significant effect on the ocular microenvironment to prevent inflammation and autoimmune disease. Since the RPE produce negative regulators of inflammation that induce suppressor activity in the microglial cells, it indicates that there is an important communication link between the cells to maintain ocular immune privilege and retinal health.
CONCLUSIONS
Our understanding of the mechanisms of ocular immune privilege has moved beyond the original description of a tissue site that is isolated from the immune system by a blood barrier and lack of direct lym- 73, 75, 113, 115, [142] [143] [144] This therapy has the capacity of generating immune tolerance with potential long-term immunosuppression. 73, 115, 144 Whether -MSH reestablishes all mechanisms of immune privilege is to be seen; moreover, as research progresses the potential of other negative regulators being important in reestablishing ocular immune privilege will definitely be found. The advantage of using the eye's own negative regulators of inflammation is that the eye is already well tolerant to these molecules, and is already set to be receptive to their anti-inflammatory activity. 
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